NKTR Valuation

Nektar Therapeutics

Add to Watchlist

Advanced Chart

55.970

+0.85(1.542%)1D

NKTR Relative Valuation

NKTR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NKTR is overvalued; if below, it's undervalued.

Historical Valuation

Nektar Therapeutics (NKTR) is now in the Fair zone, suggesting that its current forward PS ratio of 55.12 is considered Fairly compared with the five-year average of -2.86. The fair price of Nektar Therapeutics (NKTR) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：55.12

Fair

-5.56

Trailing

Forward

-6.82

EV/EBITDA

Nektar Therapeutics. (NKTR) has a current EV/EBITDA of -6.82. The 5-year average EV/EBITDA is -2.09. The thresholds are as follows: Strongly Undervalued below -6.58, Undervalued between -6.58 and -4.34, Fairly Valued between 0.15 and -4.34, Overvalued between 0.15 and 2.40, and Strongly Overvalued above 2.40. The current Forward EV/EBITDA of -6.82 falls within the Strongly Undervalued range.

-7.13

EV/EBIT

Nektar Therapeutics. (NKTR) has a current EV/EBIT of -7.13. The 5-year average EV/EBIT is -1.95. The thresholds are as follows: Strongly Undervalued below -6.13, Undervalued between -6.13 and -4.04, Fairly Valued between 0.14 and -4.04, Overvalued between 0.14 and 2.23, and Strongly Overvalued above 2.23. The current Forward EV/EBIT of -7.13 falls within the Strongly Undervalued range.

55.12

Nektar Therapeutics. (NKTR) has a current PS of 55.12. The 5-year average PS is 10.53. The thresholds are as follows: Strongly Undervalued below -11.64, Undervalued between -11.64 and -0.56, Fairly Valued between 21.62 and -0.56, Overvalued between 21.62 and 32.71, and Strongly Overvalued above 32.71. The current Forward PS of 55.12 falls within the Strongly Overvalued range.

-5.86

P/OCF

Nektar Therapeutics. (NKTR) has a current P/OCF of -5.86. The 5-year average P/OCF is -3.59. The thresholds are as follows: Strongly Undervalued below -10.25, Undervalued between -10.25 and -6.92, Fairly Valued between -0.26 and -6.92, Overvalued between -0.26 and 3.07, and Strongly Overvalued above 3.07. The current Forward P/OCF of -5.86 falls within the Historic Trend Line -Fairly Valued range.

-6.39

P/FCF

Nektar Therapeutics. (NKTR) has a current P/FCF of -6.39. The 5-year average P/FCF is -3.10. The thresholds are as follows: Strongly Undervalued below -31.53, Undervalued between -31.53 and -17.32, Fairly Valued between 11.11 and -17.32, Overvalued between 11.11 and 25.33, and Strongly Overvalued above 25.33. The current Forward P/FCF of -6.39 falls within the Historic Trend Line -Fairly Valued range.

Nektar Therapeutics (NKTR) has a current Price-to-Book (P/B) ratio of -28.36. Compared to its 3-year average P/B ratio of 1.00 , the current P/B ratio is approximately -2924.20% higher. Relative to its 5-year average P/B ratio of 1.67, the current P/B ratio is about -1795.21% higher. Nektar Therapeutics (NKTR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -119.63%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -82.44% , the current FCF yield is about -100.00% lower.

-28.36

P/B

Median3y

1.00

Median5y

1.67

0.00

FCF Yield

Median3y

-119.63

Median5y

-82.44

Competitors Valuation Multiple

The average P/S ratio for NKTR's competitors is 26.28, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR) exhibits a P/S ratio of 55.12, which is 109.73% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Oric Pharmaceuticals Inc

12.55

1.20B

AMPH.O

Amphastar Pharmaceuticals Inc

Collegium Pharmaceutical Inc

42.30

31.42%

1.34B

Performance Decomposition

Market capitalization of NKTR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NKTR in the past 1 year is driven by Unknown.